Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 1, 2022, at the 2022 Annual Meeting of Shareholders of TransMedics Group, Inc. (the "Company"), the shareholders of the Company voted on the following proposals:

Proposal One: The shareholders elected Waleed H. Hassanein, M.D., James R. Tobin, Edward M. Basile, Thomas J. Gunderson, Edwin M. Kania, Stephanie Lovell, Merilee Raines and David Weill, M.D. as directors, each to serve on the board of directors of the Company until the 2023 annual meeting of the Company's shareholders to be held in 2023 or until his or her successor is duly elected and qualified in accordance with our restated articles of organization and amended and restated bylaws, or his or her earlier death, resignation or removal, based on the following votes:



                                                                           Broker
Director Nominee               For            Against       Abstain       Non-Votes
Waleed H. Hassanein, M.D     17,917,790          40,113        8,432       2,924,020
James R. Tobin               14,666,384       3,289,850       10,101       2,924,020
Edward M. Basile             16,297,811       1,658,823        9,701       2,924,020
Thomas J. Gunderson          17,296,320         660,314        9,701       2,924,020
Edwin M. Kania               17,796,887         159,748        9,700       2,924,020
Stephanie Lovell             17,846,232         110,709        9,394       2,924,020
Merilee Raines               17,296,218         660,319        9,798       2,924,020
David Weill, M.D.            17,275,133         681,802        9,400       2,924,020

Proposal Two: The shareholders did not approve, on a non-binding advisory basis, the compensation paid to the Company's named executive officers, based on the following votes:



   For       Against     Abstain   Broker Non-Votes
7,542,657   10,404,369   19,309       2,924,020

Proposal Three: The shareholders approved, on a non-binding advisory basis, holding a shareholder advisory vote on executive compensation every year, based on the following votes:

1 Year 2 Years 3 Years Abstain Broker Non-Votes 17,876,023 5,633 62,507 22,172 2,924,020

Proposal Four: The shareholders did not approve the Amended and Restated TransMedics Group, Inc. 2019 Stock Incentive Plan, based on the following votes:

For Against Abstain Broker Non-Votes 7,363,359 10,582,739 20,237 2,924,020

Proposal Five: The shareholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2022, based on the following votes:



   For       Against   Abstain
20,011,323   873,426    5,606

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses